Conserved Protein Domain Family
7tmA_PGE2_EP1

?
cd15144: 7tmA_PGE2_EP1 
prostaglandin E2 receptor EP1 subtype, member of the class A family of seven-transmembrane G protein-coupled receptors
Prostaglandin E2 receptor EP1, also called prostanoid EP1 receptor, is one of four receptor subtypes whose endogenous physiological ligand is prostaglandin E2 (PGE2). Each of these subtypes (EP1-EP4) have unique but overlapping tissue distributions that activate different intracellular signaling pathways. It has been shown that stimulation of the EP1 receptor by PGE2 causes smooth muscle contraction and increased intracellular Ca2+ levels; however, it is still unclear whether EP1 receptor is exclusively coupled to G(q/11), which leading to activation of phospholipase C and phosphatidylinositol hydrolysis. Prostanoids are the cyclooxygenase (COX) metabolites of arachidonic acid, which include the prostaglandins (PGD2, PGE2, PGF2alpha), prostacyclin (PGI2), and thromboxane A2 (TxA2). These five major bioactive prostanoids acts as mediators or modulators in a wide range of physiological and pathophysiological processes within the kidney and play important roles in inflammation, platelet aggregation, and vasoconstriction/relaxation, among many others. They act locally by preferentially interacting with G protein-coupled receptors designated DP, EP. FP, IP, and TP, respectively. The phylogenetic tree suggests that the prostanoid receptors can be grouped into two major branches: G(s)-coupled (DP1, EP2, EP4, and IP) and G(i)- (EP3) or G(q)-coupled (EP1, FP, and TP), forming three clusters.
Statistics
?
PSSM-Id: 320272
View PSSM: cd15144
Aligned: 6 rows
Threshold Bit Score: 332.125
Threshold Setting Gi: 83287886
Created: 15-Dec-2013
Updated: 26-Jul-2017
Structure
?
Aligned Rows:
  next features
Feature 1:putative ligand binding pocket [chemical binding site]
Evidence:
  • Comment:based on the structures of some class A family members with bound ligands (peptides or chemicals), agonists, or antagonists
  • Comment:Small-molecule chemical ligands tend to bind deeper within the receptor core, compared to a peptide ligand neurotensin, which binds towards the extracelllular surface of its receptor.

Sequence Alignment
?
Format: Row Display: Color Bits: Type Selection:
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                                                                      #  ##             
gi 83287886   33 GASPALPIFSMTLGAVSNLLALALLAQAAGRLRRRrsaatFLLFVASLLATDLAGHVIPGALVLRLYt-----AGRAPAG 107
gi 260619545  41 PPAFGMSYFTMTLGALSNLTALAILAHSYASFRRRak-vpFLLLASTLLLSDLAGHLITGALALNLHlervkhHGQMEVE 119
gi 260619543  43 LSGPIAAMLSMTLGILSNIVALLIPANAYARLRRRsk--aFLLFAGSLVATDFVGHVIPGAIVMRLYl-----SGGVPAE 115
gi 632985569  28 AASMAMPIFSMTLGILSNIVALVILVKSYSRFRRRtk-atFLLFASSLVLTDFAGHLIPGALVLHQY------STVAPRR 100
gi 556977264  29 SASAAVPSFSMTLGAMSNIIALVILVKSYARFRRRsk-atFLLFASSLVITDFAGHVIPGAIVLRLY------TVQMPSM 101
gi 637266492  32 PSSPAFPIFSMTLGAVSNIVALVILVQSYARFRRRsk-atFLLFASSLVITDLAGHVIPGSFVLHLYa-----TRRGWAA 105
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                ###### ##  #                                            # #####         
gi 83287886  108 G------ACHFLGGCMVFFGLCPLLLGCGMAVERCVGVTrpllHAARVsVARARLALAAVAAVALAVALLPLARVGRYel 181
gi 260619545 120 Ppr---iYCKLFGACMVFFGLCPLLLGSAMAVERCIGITqpllHSTVVtMTRVRFSVLLITSMALTLAGLPLLNVGNYkp 196
gi 260619543 116 EynradpLCQFLGGSMVFFGLCPLFLGCAMAAERCLGVTkpllHASLVtTTRTKLSLSVIWLAALCVALLPCFQLGSYty 195
gi 632985569 101 NmgsssaLCQFFGACMVFFGLCPLFLGCVMAVERCVGVTrpllHSSVVtTARTKLAVVSLWTVAVLISLLPSMGFGRYsv 180
gi 556977264 102 Ees--ghLCQFFGTCMVFFGLCPLFLGCVMAVERCVGVTrpllHSFIVtSTRTKLTLLAIWMFALFVSLLPTFKFGSYgr 179
gi 637266492 106 Mdps-gaLCQFFGASMVFFGLCPLFLGFIMAVERCVGITrpllHAALVtPRRTKLSLLGLWAAALAIALMPLCRFGTYvn 184
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                           #  ### ### ##                                                
gi 83287886  182 QYPGTWCFIglgp--pggwRQALLAGLFASLGLVALLAALVCNTLSGLALlrarwrrrsrrpppasgpdsrrrwgahgpr 259
gi 260619545 197 QFPGTWCFLpvng--plsiADVSLTLAFSILGLLTLIVSLVSNTLSGLKLlqarikdgclkssa---------------- 258
gi 260619543 196 QYPGTWCFIkvle--daekADMAFVMLFSGLGLTSLAVALVCNTISGLTLvlgrirkk---------------------- 251
gi 632985569 181 QWPNTWCFIrvppfqpgswLDSAFAIIFSLLGLASLLVSMVCNTISGVTLvqarlrkk---------------------- 238
gi 556977264 180 QFPGTWCFIkvqn--ictwDELAFALLFSLLGLASLFLSLVCNIISGVTLmrarlkkl---------------------- 235
gi 637266492 185 QAQGAWCFIkaqk--veawPEVAFALLFSLLGLASLLASLICNTFSGLILvrarlrgqr--------------------- 241
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                                                          #  ## ##  #               ## #
gi 83287886  260 sasassassiasastffggsrssgsarrarAHDVEMVGQLVGIMVVSCICWSPMLVLVALAVggws-------stsLQRP 332
gi 260619545 259 -----------------arrhgsfsssslhSLDVEMMTQLAVITVVSCVCWSPFLIYILMSVsrfyegv-srpkhqCEKL 320
gi 260619543 252 ----------------------pcnrrsarSHDIEMVVQLVGIMVTSCICWSPLLIVGLITVkqsyehsigddlatYKTL 309
gi 632985569 239 -----------------------tcnrkakSHDIEMVVQLVGIMMVSCICWSPLLCFVLIAVcsrs-------hdqQEKR 288
gi 556977264 236 -----------------------nrnrrakSHDIEMVVQLVGIMVVSCICWSPILIFVVISVstvys----snmehFNYL 288
gi 637266492 242 ----------------------kcgqrrakAHDIEMVVQLVGIMVVSCICWSPLLVFVILSVsnsh------gdldYGKL 293
                        330       340       350
                 ....*....|....*....|....*....|.
Feature 1        ##  #  ##                      
gi 83287886  333 LFLAVRLASWNQILDPWVYILLRqaVLRQLL 363
gi 260619545 321 FLLALRLASWNQILDPWVYILLRraVLRRVL 351
gi 260619543 310 MIMGVRIASWNQILDPWVYILLRrsVLQKIY 340
gi 632985569 289 ILLGVHLASWNQILDPWVYILLRraVMRKVY 319
gi 556977264 289 MFLGVRLAAWNQILDPWVYILLRraVMKKVY 319
gi 637266492 294 LFLGVRLASWNQILDPWVYILLRraVLRKIL 324

| Disclaimer | Privacy statement | Accessibility |
NCBI Home NCBI Search NCBI SiteMap